OLIPASS Receives USD 602,000 from Vanda Pharmaceuticals for Joint R&D - Revenue Recognition Expected to Boost Earnings
Received USD 602,000 (approx. 0.78B KRW) in R&D fees from Vanda Pharmaceuticals for joint drug development.
The amount exceeds 10% of 2022 sales (approx. 2.3B KRW), requiring mandatory disclosure.
Confidential hold lifted and now amended; fees recognized as R&D revenue, positively impacting earnings.
No direct capital change, but expected to enhance enterprise value through increased revenue.
[AI Summary]This disclosure confirms receipt of R&D fees from Vanda, recognized as revenue, which should positively impact earnings; however, no capital change or further profitability details suggest a mild positive impact on stock price.
KOSDAQ Filing Information
Filing: [Correction of Description] Major Management Matters Related To Investment Decision (Receipt Of R&D Expenses For Joint Research And Development Of New Drug)